David Daniels, MD
Urology · Dakota Dunes, SDNPI 1538394952
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 175 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 41 manufacturers, the largest accounting for just 11.9% — the pattern of someone who eats at a lot of different presentations.
Across 175 payments — averaging $18.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$382
- Sumitomo Pharma America, Inc.$325
- Johnson & Johnson$225
- Myriad Genetic Laboratories, Inc.$208
- AbbVie$204
- Histosonics, Inc.$171
- plus $2K from 35 others
What the payments were for
- Food & beverage$3,208100%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 27 | $382 |
| Sumitomo Pharma America, Inc. | 25 | $325 |
| Johnson & Johnson | 11 | $225 |
| Myriad Genetic Laboratories, Inc. | 4 | $208 |
| AbbVie | 10 | $204 |
| Histosonics, Inc. | 1 | $171 |
| Boston Scientific | 8 | $152 |
| 180 Medical, Inc. | 7 | $124 |
| Pfizer | 6 | $123 |
| Axonics, Inc. | 6 | $113 |
| Medtronic | 3 | $106 |
| Tolmar Pharmaceuticals, Inc. | 6 | $99 |
| Novartis | 3 | $83 |
| Amgen | 5 | $76 |
| Merck | 4 | $71 |
| Urogen Pharma, Inc. | 4 | $68 |
| Myovant Sciences Inc. | 3 | $60 |
| Tolmar, Inc. | 3 | $58 |
| Dendreon Pharmaceuticals LLC | 3 | $56 |
| EDAP Technomed Inc | 3 | $45 |
| Abbott | 2 | $40 |
| E.r. Squibb & Sons, L.L.C. | 2 | $38 |
| Amarin Pharma, Inc. | 2 | $35 |
| Progenics Pharmaceuticals, Inc. | 2 | $32 |
| Endo Pharmaceuticals Inc. | 2 | $31 |
| Ferring Pharmaceuticals Inc. | 2 | $29 |
| Bayer | 2 | $29 |
| Dornier Medtech America, Inc | 1 | $29 |
| Endo USA, Inc. | 2 | $29 |
| Coloplast | 2 | $26 |
| Teleflex LLC | 1 | $19 |
| Accord Healthcare, Inc. | 1 | $18 |
| Calyxo, Inc. | 1 | $17 |
| Foundation Medicine, Inc. | 1 | $17 |
| Photocure Inc | 1 | $16 |
| AstraZeneca | 1 | $13 |
| Biohaven Pharmaceuticals, Inc. | 1 | $13 |
| Esperion Therapeutics, Inc. | 1 | $12 |
| KARL Storz Endoscopy-america | 1 | $12 |
| Travere Therapeutics, Inc. | 4 | $7 |
| Laborie Medical Technologies Corp. | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prolaris$164
How this compares
$3,215 in reported general payments places this provider in the 80th percentile of 40 urology providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 47 | $643,259 |
| ErleadaApalutamide | 15 | $218,892 |
| NubeqaDarolutamide | 13 | $179,993 |
| MyrbetriqMirabegron | 193 | $92,072 |
| OrgovyxRelugolix | 27 | $69,393 |
| Abiraterone Acetate | 13 | $22,895 |
| ElmironPentosan Polysulfate Sodium | 11 | $14,254 |
| Tamsulosin Hcl | 521 | $8,219 |
| GemtesaVibegron | 12 | $5,848 |
| Finasteride | 449 | $5,080 |
| Methenamine Hippurate | 61 | $3,087 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 139 | $2,985 |
| Trospium Chloride | 66 | $2,289 |
| Oxybutynin Chloride ErOxybutynin Chloride | 82 | $1,782 |
| Doxycycline Monohydrate | 57 | $1,620 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $382 | $735,331240 claims |
| Johnson & JohnsonErleada | $225 | $218,89215 claims |
| BayerNubeqa | $29 | $179,99313 claims |
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $325 | $75,24039 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 40 urology providers in South Dakota.
Other urology in Dakota Dunes
- Andrew BourneDakota Dunes$6K
- Jamie OlsenDakota Dunes$4K
- Daniel OlsenDakota Dunes$3K
- Adam AlthausDakota Dunes$3K
- Timothy KneibDakota Dunes$3K
- Patrick HonnerDakota Dunes$1K
- Kenneth McCallaDakota Dunes$143
- John WolpertDakota Dunes$95
- David HowardDakota Dunes$83
- Patrick WalshDakota Dunes$53
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.